Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Guay

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Pharmacotherapy|January 23, 1999
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's diseaseD R Guay
DICP : the Annals of Pharmacotherapy|January 1, 1990
Oral fluoroquinolone versus mono- or combination parenteral therapy in the management of bacterial infections: a critical appraisalD R Guay
Pharmacoeconomics|November 4, 1995
Formulary management of macrolide antibioticsD R Guay
Pharmacoeconomics|April 8, 1993
Sequential antimicrobial therapy: a realistic approach to cost containment?D R Guay
Drug Intelligence & Clinical Pharmacy|December 1, 1982
Cinoxacin (Cinobac, Eli Lilly & Co.)D R Guay
The Annals of Pharmacotherapy|July 1, 1996
Nontuberculous mycobacterial infectionsD R Guay
The Annals of Pharmacotherapy|September 20, 1997
Ceftibuten: a new expanded-spectrum oral cephalosporinD R Guay
Pharmacotherapy|January 1, 1992
The role of the fluoroquinolonesD R Guay
Pharmacotherapy|December 17, 1998
Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitusD R Guay
Drug Intelligence & Clinical Pharmacy|February 1, 1983
Netilmicin (Netromycin, Schering-Plough)D R Guay
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Pharmacotherapy|January 23, 1999
Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's diseaseD R Guay
DICP : the Annals of Pharmacotherapy|January 1, 1990
Oral fluoroquinolone versus mono- or combination parenteral therapy in the management of bacterial infections: a critical appraisalD R Guay
Pharmacoeconomics|November 4, 1995
Formulary management of macrolide antibioticsD R Guay
Pharmacoeconomics|April 8, 1993
Sequential antimicrobial therapy: a realistic approach to cost containment?D R Guay
Drug Intelligence & Clinical Pharmacy|December 1, 1982
Cinoxacin (Cinobac, Eli Lilly & Co.)D R Guay
The Annals of Pharmacotherapy|July 1, 1996
Nontuberculous mycobacterial infectionsD R Guay
The Annals of Pharmacotherapy|September 20, 1997
Ceftibuten: a new expanded-spectrum oral cephalosporinD R Guay
Pharmacotherapy|January 1, 1992
The role of the fluoroquinolonesD R Guay
Pharmacotherapy|December 17, 1998
Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitusD R Guay
Drug Intelligence & Clinical Pharmacy|February 1, 1983
Netilmicin (Netromycin, Schering-Plough)D R Guay
Pageof 9